Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 10 Interest Coverage is 444.00 as of May. 2026, which is 96% below its 10-year median of 10,000.00. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 376 Biotechnology companies, Heidelberg Pharma AG ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Heidelberg Pharma AG's
Operating Income
for the
three
months ended in May. 2026 was €0.44 Mil. Heidelberg Pharma AG's Interest Expense for the
three
months ended in May. 2026 was €-0.00 Mil.
Heidelberg Pharma AG's interest coverage for the quarter that ended in May. 2026 was 444.00.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Heidelberg Pharma AG's Interest Coverage or its related term are showing as below:
WBO:HPHA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025 * Ranked among companies with meaningful Interest Coverage only.
Heidelberg Pharma AG (WBO:HPHA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Heidelberg Pharma AG Interest Coverage Related Terms
Heidelberg Pharma AG Interest Coverage Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WBO:HPHA vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Interest Coverage falls into.
Heidelberg Pharma AG Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (WBO:HPHA) has a Interest Coverage of 444.00 as of May. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Heidelberg Pharma AG and its competitors. This is 96% below median its historical median of 10,000.00. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 376 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's Interest Coverage too high?
Heidelberg Pharma AG's current Interest Coverage of 444.00 is 96% below median its 10-year median of 10,000.00. The Biotechnology industry median Interest Coverage is 104.03. Heidelberg Pharma AG's value of 444.00 is 326.8% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 376 companies for Interest Coverage. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Interest Coverage is 104.03. Heidelberg Pharma AG's value of 444.00 is 326.8% above this benchmark. While the company's 10-year median is 10,000.00 vs. the industry median of 104.03, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Interest Coverage of 444.00 is 326.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Interest Coverage is 444.00, which is 96% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current Interest Coverage is 444.00, which is 96% below median its 10-year median of 10,000.00 and 326.8% above the Biotechnology industry median of 104.03. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Interest Coverage is 444.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87.
GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.
Key valuation signals for WBO:HPHA:
Interest Coverage: 444.00 (96% below median its 10-year median of 10,000.00)
GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
Industry Position: 326.8% above the Biotechnology median (#999999 of 376)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
